KFAS
SNDX icon

Keating Financial Advisory Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Keating Financial Advisory Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$93 – 2703
2026
Q1 		$93 Buy
+4
New +$87 ﹤0.01% 2412

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Keating Financial Advisory Services's SNDX Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 4 shares — an estimated $93 sold.

Keating Financial Advisory Services first reported a position in SNDX in Q1 2026 and held it in 1 quarter. The position peaked at $93 in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 4 Syndax Pharmaceuticals shares in Q2 2026, an estimated $93.
  • Keating Financial Advisory Services first reported a position in Syndax Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Keating Financial Advisory Services's Syndax Pharmaceuticals position peaked at $93 in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.